{"success":true,"data":{"pressRelease":{"id":"157234","rtpr_id":"nGNX7SxrXj-20260930","ticker":"SCNX","exchange":"NASDAQ","all_tickers":["SCNX"],"title":"Scienture Holdings, Inc. Announces Reverse Stock Split","author":"Globe Newswire","published_at":"2026-09-30T20:05:00.231Z","article_body":"COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.\n(NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned\npharmaceutical operating companies focused on providing enhanced value to\npatients, physicians and caregivers through the development,\ncommercialization, and distribution of novel specialty products that address\nunmet market needs, today announced that it has determined to effect a reverse\nstock split of its outstanding shares of common stock at a ratio of 1-for-25.\nThe reverse stock split is expected to take effect before markets open on\nMonday, October 5, 2026. The Company’s common stock will continue to be\ntraded on the Nasdaq Capital Market under the symbol “SCNX” and will begin\ntrading on a split-adjusted basis when the market opens on Monday, October 5,\n2026. The new CUSIP number for the Company’s common stock following the\nreverse stock split will be 80880X203. As of September 30, 2026, the Company\nhas 41,064,146 shares of common stock issued and outstanding. Following the\nreverse stock split, the Company expects to have approximately 1,642,565\nshares of common stock issued and outstanding.\n\nThe reverse stock split is intended to enable the Company to achieve several\nimportant corporate objectives, including enabling the Company to maintain\ncompliance with the minimum bid price requirement under Nasdaq’s continued\nlisting criteria and making additional shares of common stock available for\nfuture issuance.\n\nAt the effective time of the reverse stock split, every 25 shares of the\nCompany’s issued and outstanding common stock will be converted\nautomatically into one issued and outstanding share of common stock without\nany change in the par value per share. Stockholders holding shares through a\nbrokerage account will have their shares automatically adjusted to reflect the\n1-for-25 reverse stock split. The reverse split will not result in any change\nin the par value per share or the total number of authorized shares of common\nstock.\n\nThe reverse stock split will affect all stockholders uniformly and will not\nalter any stockholder’s percentage interest in the Company’s equity,\nexcept to the extent that the reverse stock split would result in a\nstockholder owning a fractional share. No fractional shares will be issued in\nconnection with the reverse stock split. Stockholders of record otherwise\nentitled to receive a fractional shares as a result of the reverse stock split\nwill receive a cash payment in lieu of such fractional share. Proportional\nadjustments will be made to the number of shares of the Company’s common\nstock issuable upon exercise or conversion of the Company’s equity awards,\nconvertible preferred stock and warrants, as well as the applicable exercise\nor conversion price. Stockholders with shares in brokerage accounts should\ndirect any questions concerning the reverse stock split to their broker; all\nother stockholders may direct questions to the Company’s transfer agent,\nContinental Stock Transfer & Trust Company.\n\nAbout Scienture Holdings, Inc.\n\nSCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary,\nScienture, LLC, is a comprehensive pharmaceutical product company focused on\nproviding enhanced value to patients, physicians and caregivers by offering\nnovel specialty products to satisfy unmet market needs. Scienture, LLC is a\nbranded, specialty pharmaceutical company consisting of a highly experienced\nteam of industry professionals who are passionate about developing and\nbringing to market unique specialty products that provide enhanced value to\npatients and healthcare systems. The assets in development at Scienture are\nacross therapeutics areas, indications and cater to different market segments\nand channels. For more information please visit: www.scientureholdings.com and\nwww.scienture.com.\n\nCautionary Statements Regarding Forward-Looking Statements\n\nThis press release contains certain statements that may be deemed to be\n“forward-looking statements” within the federal securities laws, including\nthe safe harbor provisions under the Private Securities Litigation Reform Act\nof 1995. Statements that are not historical are forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section\n21E of the Securities Exchange Act of 1934. Forward-looking statements relate\nto future events or our future performance or future financial condition.\nThese forward-looking statements are not historical facts, but rather are\nbased on current expectations, estimates and projections about our company,\nour industry, our beliefs and our assumptions. Such forward-looking statements\ninclude, but are not limited to, statements regarding our or our management\nteam’s expectations, hopes, beliefs, intentions or strategies regarding the\nfuture, including for the intended reverse stock split and the products we may\nlaunch, the success those products may have in the marketplace, and our\nstrategies related to those products. In addition, any statements that refer\nto projections, forecasts or other characterizations of future events or\ncircumstances, including any underlying assumptions, are forward-looking\nstatements. In some cases, you can identify forward-looking statements by the\nfollowing words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,” or\nthe negative of these terms or other similar expressions, but the absence of\nthese words does not mean that a statement is not forward-looking.\nForward-looking statements are subject to a number of risks and uncertainties\n(some of which are beyond our control) that may cause actual results or\nperformance to be materially different from those expressed or implied by such\nforward-looking statements. Accordingly, readers should not place undue\nreliance on any forward-looking statements. These risks include risks relating\nto agreements with third parties; our ability to raise funding in the future,\nas needed, and the terms of such funding, including potential dilution caused\nthereby; our ability to continue as a going concern; security interests under\ncertain of our credit arrangements; our ability to maintain the listing of our\ncommon stock on The Nasdaq Stock Market LLC; claims relating to alleged\nviolations of intellectual property rights of others; the outcome of any\ncurrent legal proceedings or future legal proceedings that may be instituted\nagainst us; unanticipated difficulties or expenditures relating to our\nbusiness plan; and those risks detailed in our most recent Annual Report on\nForm 10-K, as amended, and subsequent reports filed with the Securities and\nExchange Commission.\n\nForward-looking statements speak only as of the date they are made. Scienture\nHoldings, Inc. undertakes no obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise that occur after that date, except as otherwise provided\nby law.\n\nContact:\n\nSCIENTURE HOLDINGS, INC.\n20 Austin Blvd\nCommack, NY 11725\nEmail: IR@Scienture.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f177940-bb59-4f95-a316-0ca68e549ea4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7SxrXj-20260930","title":"Scienture Holdings, Inc. Announces Reverse Stock Split","author":"Globe Newswire","ticker":"SCNX","created":"2026-09-30T20:05:00.231Z","tickers":["SCNX"],"exchange":"NASDAQ","article_body":"COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.\n(NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned\npharmaceutical operating companies focused on providing enhanced value to\npatients, physicians and caregivers through the development,\ncommercialization, and distribution of novel specialty products that address\nunmet market needs, today announced that it has determined to effect a reverse\nstock split of its outstanding shares of common stock at a ratio of 1-for-25.\nThe reverse stock split is expected to take effect before markets open on\nMonday, October 5, 2026. The Company’s common stock will continue to be\ntraded on the Nasdaq Capital Market under the symbol “SCNX” and will begin\ntrading on a split-adjusted basis when the market opens on Monday, October 5,\n2026. The new CUSIP number for the Company’s common stock following the\nreverse stock split will be 80880X203. As of September 30, 2026, the Company\nhas 41,064,146 shares of common stock issued and outstanding. Following the\nreverse stock split, the Company expects to have approximately 1,642,565\nshares of common stock issued and outstanding.\n\nThe reverse stock split is intended to enable the Company to achieve several\nimportant corporate objectives, including enabling the Company to maintain\ncompliance with the minimum bid price requirement under Nasdaq’s continued\nlisting criteria and making additional shares of common stock available for\nfuture issuance.\n\nAt the effective time of the reverse stock split, every 25 shares of the\nCompany’s issued and outstanding common stock will be converted\nautomatically into one issued and outstanding share of common stock without\nany change in the par value per share. Stockholders holding shares through a\nbrokerage account will have their shares automatically adjusted to reflect the\n1-for-25 reverse stock split. The reverse split will not result in any change\nin the par value per share or the total number of authorized shares of common\nstock.\n\nThe reverse stock split will affect all stockholders uniformly and will not\nalter any stockholder’s percentage interest in the Company’s equity,\nexcept to the extent that the reverse stock split would result in a\nstockholder owning a fractional share. No fractional shares will be issued in\nconnection with the reverse stock split. Stockholders of record otherwise\nentitled to receive a fractional shares as a result of the reverse stock split\nwill receive a cash payment in lieu of such fractional share. Proportional\nadjustments will be made to the number of shares of the Company’s common\nstock issuable upon exercise or conversion of the Company’s equity awards,\nconvertible preferred stock and warrants, as well as the applicable exercise\nor conversion price. Stockholders with shares in brokerage accounts should\ndirect any questions concerning the reverse stock split to their broker; all\nother stockholders may direct questions to the Company’s transfer agent,\nContinental Stock Transfer & Trust Company.\n\nAbout Scienture Holdings, Inc.\n\nSCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary,\nScienture, LLC, is a comprehensive pharmaceutical product company focused on\nproviding enhanced value to patients, physicians and caregivers by offering\nnovel specialty products to satisfy unmet market needs. Scienture, LLC is a\nbranded, specialty pharmaceutical company consisting of a highly experienced\nteam of industry professionals who are passionate about developing and\nbringing to market unique specialty products that provide enhanced value to\npatients and healthcare systems. The assets in development at Scienture are\nacross therapeutics areas, indications and cater to different market segments\nand channels. For more information please visit: www.scientureholdings.com and\nwww.scienture.com.\n\nCautionary Statements Regarding Forward-Looking Statements\n\nThis press release contains certain statements that may be deemed to be\n“forward-looking statements” within the federal securities laws, including\nthe safe harbor provisions under the Private Securities Litigation Reform Act\nof 1995. Statements that are not historical are forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933 and Section\n21E of the Securities Exchange Act of 1934. Forward-looking statements relate\nto future events or our future performance or future financial condition.\nThese forward-looking statements are not historical facts, but rather are\nbased on current expectations, estimates and projections about our company,\nour industry, our beliefs and our assumptions. Such forward-looking statements\ninclude, but are not limited to, statements regarding our or our management\nteam’s expectations, hopes, beliefs, intentions or strategies regarding the\nfuture, including for the intended reverse stock split and the products we may\nlaunch, the success those products may have in the marketplace, and our\nstrategies related to those products. In addition, any statements that refer\nto projections, forecasts or other characterizations of future events or\ncircumstances, including any underlying assumptions, are forward-looking\nstatements. In some cases, you can identify forward-looking statements by the\nfollowing words: “anticipate,” “believe,” “continue,” “could,”\n“estimate,” “expect,” “intend,” “may,” “ongoing,”\n“plan,” “potential,” “predict,” “project,” “should,” or\nthe negative of these terms or other similar expressions, but the absence of\nthese words does not mean that a statement is not forward-looking.\nForward-looking statements are subject to a number of risks and uncertainties\n(some of which are beyond our control) that may cause actual results or\nperformance to be materially different from those expressed or implied by such\nforward-looking statements. Accordingly, readers should not place undue\nreliance on any forward-looking statements. These risks include risks relating\nto agreements with third parties; our ability to raise funding in the future,\nas needed, and the terms of such funding, including potential dilution caused\nthereby; our ability to continue as a going concern; security interests under\ncertain of our credit arrangements; our ability to maintain the listing of our\ncommon stock on The Nasdaq Stock Market LLC; claims relating to alleged\nviolations of intellectual property rights of others; the outcome of any\ncurrent legal proceedings or future legal proceedings that may be instituted\nagainst us; unanticipated difficulties or expenditures relating to our\nbusiness plan; and those risks detailed in our most recent Annual Report on\nForm 10-K, as amended, and subsequent reports filed with the Securities and\nExchange Commission.\n\nForward-looking statements speak only as of the date they are made. Scienture\nHoldings, Inc. undertakes no obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise that occur after that date, except as otherwise provided\nby law.\n\nContact:\n\nSCIENTURE HOLDINGS, INC.\n20 Austin Blvd\nCommack, NY 11725\nEmail: IR@Scienture.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1f177940-bb59-4f95-a316-0ca68e549ea4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T20:05:00.346071068Z","server_sent_at_ms":1790798700346},"received_at":"2026-09-30T20:05:00.434Z","source_url":null},"analysis":{"id":"145909","press_release_id":"157234","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["1-for-25 reverse split to maintain Nasdaq minimum bid price compliance","split intended to make additional shares available for future issuance (dilution risk)","forward-looking statements disclose going concern and funding/dilution risks"],"eventType":"reverse_split","narrative":"Scienture Holdings announced a 1-for-25 reverse stock split effective before market open on October 5, 2026, with shares continuing to trade on Nasdaq under SCNX.\n\nThe split will cut shares outstanding from 41,064,146 to approximately 1,642,565 and is intended to maintain compliance with Nasdaq's minimum bid price requirement while making additional shares available for future issuance.\n\nA reverse split aimed at bid-price compliance signals listing-compliance risk, and the stated intent to free up shares for future issuance hints at potential dilution ahead.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Steep 1-for-25 reverse split underscores Nasdaq listing-compliance pressure and sets up potential future dilution."},"keyFigures":{"customDimensions":{"effective_date":"2026-10-05","reverse_split_ratio":"1-for-25","shares_outstanding_pre_split":41064146,"shares_outstanding_post_split":1642565}},"quotedText":"enabling the Company to maintain compliance with the minimum bid price requirement under Nasdaq's continued listing criteria and making additional shares of common stock available for future issuance","namedEntities":{"people":[],"products":[],"companies":[{"name":"Scienture Holdings, Inc.","ticker":"SCNX","relationship":"filer"},{"name":"Scienture, LLC","relationship":"subsidiary"},{"name":"Continental Stock Transfer & Trust Company","relationship":"transfer agent"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Aggressive 1-for-25 reverse split explicitly to maintain Nasdaq minimum bid price compliance, signaling listing-compliance risk and likely prior share-price deterioration. Ratio is 1:10+."},"tickerRelevance":{"others":[],"primary":"SCNX"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"reverse-split-listing-compliance","ratioSeverity":"1:25"}},"event_type":"reverse_split","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"Scienture Holdings announced a 1-for-25 reverse stock split effective before market open on October 5, 2026, with shares continuing to trade on Nasdaq under SCNX.\n\nThe split will cut shares outstanding from 41,064,146 to approximately 1,642,565 and is intended to maintain compliance with Nasdaq's minimum bid price requirement while making additional shares available for future issuance.\n\nA reverse split aimed at bid-price compliance signals listing-compliance risk, and the stated intent to free up shares for future issuance hints at potential dilution ahead.","key_figures":{"customDimensions":{"effective_date":"2026-10-05","reverse_split_ratio":"1-for-25","shares_outstanding_pre_split":41064146,"shares_outstanding_post_split":1642565}},"named_entities":{"people":[],"products":[],"companies":[{"name":"Scienture Holdings, Inc.","ticker":"SCNX","relationship":"filer"},{"name":"Scienture, LLC","relationship":"subsidiary"},{"name":"Continental Stock Transfer & Trust Company","relationship":"transfer agent"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T20:05:05.278Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"reverse-split-listing-compliance","ratioSeverity":"1:25"}},"durationMs":4813,"modelName":"glm-5.3-flashx"}}